Early clinical trials in Denmark gets big boost
13 April 2016
A 5.7 million euro grant from Innovation Fund Denmark enables the building of two new centres for lung diseases and infectious diseases. This will significantly increase the volume of early clinical trials and establish Denmark as a preferred country for early clinical trials in patients further.
Denmark offers unique health data and excellent researchers, making the country very attractive for international pharmaceutical companies wanting to conduct clinical research and trials.
The public-private partnership, National Experimental Therapy Partnership (NEXT), is a collaboration across regions, university hospitals, universities and private pharmaceutical companies in Denmark, working to strengthen Denmark as a preferred country for early clinical research.
Read more about Greater Copenhagen’s life sciences sector.
New centres for lung diseases and infectious diseases
A new 5.7 million euro grant from Innovation Fund Denmark enables the building of two new centres for lung diseases and infectious diseases. This will significantly increase the volume of early clinical trials and establish Denmark as a preferred country for early clinical trials in patients further.
“The ambition to create the best conditions for early clinical research has now been established firmly. With the new industry partners on board, and a motivated public engagement from all Danish regions, we have created the best possible opportunities for early clinical research”, says Iben Ordrup Christensen, Executive Director, Clinical Research, MSD Denmark, Iceland & Norway.
Fewer barriers to research
NEXT is working to improve conditions for drug testing such as removing bottlenecks and barriers for public-private collaboration on clinical trials in Denmark.
“New biological medicines are being developed rapidly, and there is a need for a large number of early stage trials testing these medicines on patients with asthma, COPD and lung pulmonary fibrosis. The new specialised NEXT Respiratory Medicine Centre will focus on phase I and phase II trials at six units with broad national representation, ensuring fast inclusion of the right patients,” says Vibeke Backer, Clinical Professor and Chief Physician, Department of Clinical Medicine at Bispebjerg Hospital, which will serve as the Medical Lead for the NEXT Centre for Respiratory Medicine.
National Experimental Therapy Partnership (NEXT) is a public-private partnership between Danish regions, university hospitals and five pharmaceutical companies. The founding partners are: the Capital Region of Denmark, Region Zealand, Region Midt, Region Syd, Region Nord, University of Copenhagen, Aarhus University, Aalborg University, Bioneer, LEO Pharma, Novo Nordisk, MSD, Novartis and Roche. Read more on nextpartnership.dk
How can we help your company?
If you want to know more about doing business and life science research in Greater Copenhagen, please contact one of our business consultants.